Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.


Full Editorial Writeup
This is a Minnesota-based medical device manufacturer producing an FDA-approved acoustic wound therapy device. The product addresses chronic and complex wound care, a clinical category that grows with an aging population and rising diabetes and vascular disease rates. The company generated $11.3M in revenue in 2024 and converted it into $3.35M of EBITDA, a roughly 30 percent margin that signals real pricing power and a defensible product rather than a commodity manufacturer.
The core asset is intellectual property. With 44 issued patents protecting the device and over 20 additional healthcare technologies in the pipeline, this is a platform with a moat, not a one-product shop dependent on a single SKU. FDA approval is itself a barrier to entry that takes competitors years and millions to clear, and the patent estate compounds that protection.
Wound care is a recurring clinical need driven by demographics, not discretionary spending. Hospitals, wound care clinics, and long-term care facilities buy these devices regardless of the economic cycle because the alternative is amputation, infection, and far higher downstream costs. That makes this a durable, recession-resistant medtech franchise with optionality from an unmonetized pipeline.
Why we like it
- Earnings quality is strong with $3.35M EBITDA on $11.3M revenue, a roughly 30 percent margin that is rare for a manufacturer and signals genuine pricing power. The margin profile points to differentiated, patent-protected product economics rather than contract or commodity manufacturing where margins get squeezed to single digits.
- The moat is real and legally enforceable, anchored by 44 issued patents plus FDA approval that competitors cannot replicate without years of clinical work and capital. This combination of regulatory clearance and IP protection is exactly the kind of durable barrier that lets a small business hold share and price against larger entrants.
- Wound care rides demographic tailwinds that are independent of the economic cycle, driven by an aging population and rising diabetes, obesity, and vascular disease. Demand for chronic wound treatment grows structurally every year and is reimbursed by payers, which insulates revenue from consumer discretionary swings.
- There is embedded optionality in the 20-plus technologies in the pipeline, none of which appear monetized in the current $11.3M revenue base. An operator who can navigate FDA pathways and commercialization could turn this into a multi-product platform, meaning you are buying current cash flow plus a free call option on the roadmap.
- Wood Pallet Manufacturer & Pallet Management Services, 50-Year Illinois Operation
- Precision Metal Component Manufacturer, 50-Year Michigan Machine Shop
- High-Precision CNC Machine Shop, 30-Year Maine Manufacturer
- Temperature-Controlled Trucking Company, Cold-Chain Carrier (Relocatable, CA)
- Distinguished Powder Coating Business, 20-Year South Carolina Finisher
- 70-Year Steel Fabrication Shop, Norfolk County MA Infrastructure Contractor